title: Compensatory enlargement in transplant coronary artery disease: an intravascular ultrasound study.
abstract: BACKGROUND
  It is unclear to what extent the "Glagov phenomenon" occurs in transplant coronary artery disease (TCAD). The objective of this study was to evaluate the relationship between intimal hyperplasia and compensatory enlargement in TCAD.
  
  
  METHODS
  Intravascular ultrasound imaging was performed on 190 cardiac transplant recipients at (1.4 +/- 0.6) months and again (12.1 +/- 0.7) months after cardiac transplantation. Studies 1 year apart were matched at 625 sites. There were 345 coronary artery sites that had an increase in intimal area > 10% from baseline to one year, and this comprised the data set of the present study.
  
  
  RESULTS
  At the first year, 91% of coronary artery sites with intimal growth had a total cross-sectional area stenosis < or = 40%, but 38% of the sites showed a decrease of > 10% in lumen area. Receiver operating characteristic curve demonstrated that the change in cross-sectional area stenosis cut-off level at year 1 was 8% with a sensitivity of 75% and a specificity of 82% in predicting lumen loss. At a total cross-sectional area stenosis of 20%, sensitivity was 65% with a specificity of 81% in predicting lumen loss.
  
  
  CONCLUSIONS
  In TCAD, vessel enlargement as a compensatory mechanism for plaque growth is generally inadequate. Instead of continued vessel expansion, luminal narrowing develops when there is more than 8% cross-sectional area filled with intimal hyperplasia. In distinction to native coronary artery atherosclerotic disease, the transition point in transplant vasculopathy where the lumen is diminished by increasing intimal growth, occurs at a lower threshold, 20% vs 40% of vessel cross-sectional area.
authors.affiliation: Department of Cardiology, Peking University Third Hospital, Beijing100083, China.
authors.forename: Hai-yan
authors.initials: HY
authors.lastname: Li
authors.forename: Koji
authors.initials: K
authors.lastname: Tanaka
authors.forename: Brandy
authors.initials: B
authors.lastname: Oeser
authors.forename: Brett
authors.initials: B
authors.lastname: Wertman
authors.forename: Jon A
authors.initials: JA
authors.lastname: Kobashigawa
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Tobis
mesh_terms: D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000473:pathology*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000473:pathology*; D005260:Female; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D017539:Tunica Intima / Q000473:pathology*; D018084:Ultrasonography, Interventional
chemical_list: D009173:Mycophenolic Acid; D001379:Azathioprine